This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker-selection, combinatorial strategies, safety/toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
- ISBN: 978-3-319-63756-3
- Editorial: Springer
- Encuadernacion: Cartoné
- Páginas: 370
- Fecha Publicación: 27/10/2017
- Nº Volúmenes: 1
- Idioma: Inglés